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Proteomics is the study of proteins and their interactions in a cell. With the
completion of the Human Genome Project, the emphasis is shifting to the protein
compliment of the human organism. Because proteome reflects more accurately on
the dynamic state of a cell, tissue, or organism, much is expected from proteomics
to yield better disease markers for diagnosis and therapy monitoring. The advent
of proteomics technologies for global detection and quantitation of proteins creates
new opportunities and challenges for those seeking to gain greater understanding
of diseases. High-throughput proteomics technologies combining with advanced
bioinformatics are extensively used to identify molecular signatures of diseases
based on protein pathways and signaling cascades. Mass spectrometry plays a
vital role in proteomics and has become an indispensable tool for molecular and
cellular biology. While the potential is great, many challenges and issues remain
to be solved, such as mining low abundant proteins and integration of proteomics
with genomics and metabolomics data. Nevertheless, proteomics is the foundation
for constructing and extracting useful knowledge to biomedical research. In this
review, a snapshot of contemporary issues in proteomics technologies is discussed.
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Introduction
Proteomics is the protein equivalent of genomics and
has captured the imagination of biomolecular scien-
tists worldwide. It encompasses a broad range of
technologies aimed at determining the identity and
quantity of expressed proteins in cells, their three-
dimensional structure and interaction partners. In
the postgenomic era, proteomics is a rapidly growing
field of research that is becoming increasingly impor-
tant. For example, it is extensively applied to the
study of proteins involved in carcinogenesis, as well
as to discover biomarkers for clinical use (1 ). Dis-
ease markers are widely used for screening, diagnosis,
staging, prognosis, monitoring response to treatment,
and detection of recurrent diseases.
As protein-protein interactions are the key to sig-
nal transduction to many regulatory events, a sys-
tematic classification of protein-protein interfaces is a
valuable resource for understanding the principles of
molecular recognition and for modeling protein com-
plexes (2 ). The question of how one protein regulates
the activity of another by binding to it requires an
integration of structural, functional, and dynamic
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information. In the last decade, there have been
many improvements in protein separation tech-
niques, including two-dimensional polyacrylamide gel
electrophoresis (2-D PAGE), liquid chromatography
(LC), isotope-coded affinity tag (ICAT) labeling, and
so on. Much progress has also been recently achieved
in the analysis of proteins from tryptic digests using
mass spectrometry (MS) and database searching. The
newest generation of MS, combined with good sepa-
ration techniques, is capable of providing rapid and
confident protein identifications at the low femtomole
level (3–6 ).
From Genomics to Proteomics
With the completion of the Human Genome Project,
the emphasis is shifting to the protein compliment of
the human organism. This has given rise to the sci-
ence of proteomics, the study of all the proteins pro-
duced by cell and organism, which involves the iden-
tification of proteins in the body and the determina-
tion of their roles in physiological and pathophysiolog-
ical functions. As sequencing of the entire genomes of
many prokaryotes and eukaryotes has been completed,
there is a revival of interest in proteomics.
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The term “proteome” refers to all the proteins ex-
pressed by a genome. While a genome remains un-
changed to a large extent, the proteins in any par-
ticular cell change dramatically as genes are turned
on or off in response to the environment. Since it
is proteins that are directly involved in both normal
and disease-associated biochemical processes, a more
complete understanding of disease may be gained by
looking directly into the proteins within a diseased cell
or tissue. As a reflection of the dynamic nature of the
proteome, some researchers use the term “functional
proteome” to describe all the proteins produced by a
specific cell in a single time frame. Whilst humans are
estimated to have 30,000 to 40,000 genes potentially
encoding 40,000 different proteins, alternative RNA
splicing and post-translational modification (PTM)
may increase this number up to 2,000,000 proteins or
protein fragments (7 ). As a consequence, the pro-
teome is far more complex than the genome.
Genomics has provided a vast amount of informa-
tion linking gene activity with disease, but it does
not predict PTM that most proteins undergo. Al-
though DNA/RNA is easier to work with, there are
limitations to the information that can be derived
from DNA/RNA analysis. There are a number of rea-
sons why gene sequence information and the pattern
of gene activity in a cell do not provide a complete
and accurate profile of a protein’s abundance or its
final structure and state of activity. After synthesis
on ribosomes, proteins are cut to eliminate initiation,
transit, and signal sequences, as well as simple chem-
ical groups or complex molecules that are attached.
The gene transcript can be spliced in different ways
prior to translation into protein. Following transla-
tion, most proteins are chemically changed through
PTM, mainly through the addition of carbohydrate
and phosphate groups. Such modification plays a vi-
tal role in modulating the function of many proteins
but is not directly coded by genes. The PTMs are nu-
merous (more than 300 types have been documented),
static, and dynamic, including phosphorylation, gly-
cosylation, acetylation, deamidation, palmitoylation,
sulfation, and so on. As a consequence, the infor-
mation from a single gene can encode as many as 50
different protein species. Therefore, DNA sequence
analysis does not predict the active form of a protein
and RNA quantitation does not always reflect the
corresponding protein levels. Multiple proteins can
be obtained from each gene when PTM and mRNA
splicing are taken into account. DNA/RNA analy-
sis cannot predict the amount of a gene product, in-
cluding the type and amount of PTM when a gene is
translated, or the events involving multiple genes such
as aging, stress responses, drug responses, and patho-
logical transformations. Beyond the genomic level, it
is clear to see why genomic information often does
not provide an accurate profile of protein abundance,
structure, and activity.
Actually, genomics and proteomics are comple-
mentary fields, with proteomics extending the func-
tional analysis. It is believed that through genomics
and proteomics, new disease markers and drug tar-
gets can be identified, which will ultimately help de-
sign products to prevent, diagnose, and treat diseases.
The future of medicine and biotechnology will be im-
pacted greatly by genomics and proteomics, but there
is much needed to be done to realize the potential
benefits.
Proteomics Technologies
Two-dimensional polyacrylamide gel
electrophoresis
Over three decades, 2-D PAGE has proven to be a re-
liable and efficient method for separation of proteins
based on mass and charge. It can achieve the separa-
tion of several thousand different proteins in one gel.
High-resolution 2-D PAGE can resolve up to 10,000
protein spots per gel. Stains such as Coomassie blue,
silver, SYPRO Ruby and Deep Purple can be em-
ployed to visualize the proteins (8 ). The proteins are
separated by charge (isoelectric point) in the first di-
mension and by mass in the second dimension. In
isoelectric focusing, the proteins migrate in a pH gra-
dient to the pH at which they have no net charge.
The most common proteins are separated by isoelec-
tric point in the horizontal direction and by size in
the vertical direction.
Unfortunately, 2-D PAGE is a time-consuming
and labor-intensive process. It implies some inherent
limitations especially concerning hydrophobic and al-
kaline proteins, which are therefore often underrepre-
sented in 2-D PAGE (9 ). Besides, this technique has
low dynamic range and gel-to-gel variability. As an
improvement, fluorescence-based difference gel elec-
trophoresis overcomes the problems associated with
traditional 2-D PAGE and allows more accurate and
sensitive quantitative proteomics studies. Nowadays,
2-D PAGE analysis is often coupled with the MS tech-
nology. The 2-D PAGE with immobilized pH gradi-
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ents, IPG-Dalt, has provided higher resolution, im-
proved reproducibility, and higher loading capacity
for preparative purposes with the intent of subsequent
spot identification by MS.
Liquid chromatography
LC is a method of separating compounds within a
sample so that they can be identified and quan-
tified. There are increasing applications in proteomics
research due to its ability to analyze large, fragile
biomolecules. With advancements in ionization meth-
ods and instrumentation, LC combined with MS has
become a powerful technology for the characterization
and identification of peptides and proteins in a com-
plex mixture (10 ). The bottom-up LC-MS approach
to proteomics generally involves protease digestion
followed by LC-MS with peptide mass fingerprinting
or LC-MS/MS to derive sequence of individual pep-
tides. Another significant improvement is the de-
velopment of multidimensional protein identification
technology, which separates peptides in 2-D LC. The
separation can be interfaced directly with the ion
source of a mass spectrometer (11 ).
Isotope-coded affinity tag labeling
Quantitative proteomics has recently emerged as a
complementary technology to mRNA profiling with
the ability to comprehensively characterize the struc-
tural and functional aspects of protein species. Be-
cause of the ionization variability for different pep-
tides, the best internal standard for peptide quan-
titation is the same peptide labeled with stable iso-
topes. There are several protocols for the use of sta-
ble isotopes in proteomics, in which the ICAT label-
ing technique has received the most attention. The
relative quantification is highly accurate because it
is based on stable isotope dilution techniques (12 ).
One of the major advantages of the ICAT labeling
strategy is that the labeling reaction is compatible
with commonly used reagents for 2-D PAGE. How-
ever, the ICAT labeling technique has some limita-
tions in that it requires cystein-containing proteins
and it provides only relative quantitation. A more re-
cent development of ICAT is isobaric tags for relative
and absolute quantification (iTRAQ), in which a set
of isobaric reagents allows for the identification and
quantitation of up to four different samples simultane-
ously. The multiplexing capacity of iTRAQ provides
additional statistical validation within a given exper-
iment (13 ). Moreover, the technique offers more ex-
tensive proteome coverage and enhanced sensitivity,
making the tracking of PTMs feasible. The isobaric
nature of the gross tag requires that the quantitation
occurs in MS/MS rather than in MS mode, simplify-
ing the analysis, but necessitating higher performance
instrumentation. Anyway, the ICAT labeling strategy
has been adopted into a number of proteomics studies
(14 , 15 ).
Mass spectrometry
In order to exploit the protein profiles expressed
under different physiological and pathophysiological
conditions, protein analysis by MS is usually used
as a powerful platform in proteomics. The tech-
nology is applied for mass determination and can
be adapted for protein identification. A mass spec-
trometer separates proteins and other analytes ac-
cording to their mass-to-charge (m/z) ratio. The
molecule is ionized and the ion is propelled into a
mass analyzer by an electric field that resolves each
ion according to its m/z ratio (ionization of proteins
allows them to be propelled towards the analyzer
by virtue of charge repulsion). Then the detector
passes the information to the computer for analysis.
Frequently used ionization methods include electro-
spray ionization (ESI), matrix-assisted laser desorp-
tion/ionization (MALDI), and surface-enhanced laser
desorption/ionization (SELDI), because they cause
little or no fragmentation of the molecule during the
ionization and desorption process (Figure 1).
Electrospray ionization
This technology involves the production of gaseous
ions by application of a potential to a flowing liquid,
resulting in the formation of a spray of small droplets
with solvent-containing analyte. Solvent is removed
from the droplet by heat or another form of energy
such as collision with a gas, and multiply charged ions
are formed. As the droplet size further decreases, they
reach a point at which they become unstable and ex-
plode into even finer droplets. Finally, electrostatic
repulsion is sufficiently high to cause desorption of the
analyte ions, which are then passed to the mass spec-
trometer. Ions generated by ESI usually bear multi-
ple charges (M+nH)n+. This can be mathematically
transformed into a simple mass spectrum that reveals
the molecular weights of the fragments. A quadrupole
analyzer is frequently used with ESI. Only ions of a
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Fig. 1 The workflow of proteomics technologies. 2-D PAGE: two-dimensional polyacrylamide gel electrophoresis;
ESI: electrospray ionization; ICAT: isotope-coded affinity tag; iTRAQ: isobaric tags for relative and absolute quan-
tification; LTQ: linear ion trap quadrupole; MALDI: matrix-assisted laser desorption/ionization; MudPIT: multi-
dimensional protein identification technology; PTM: post-translational modification; SELDI: surface-enhanced laser
desorption/ionization; TOF MS: time-of-flight mass spectrometry.
certain m/z will have the correct oscillation path that
enables it to reach the detector in the presence of an
electric field. One benefit of this method for analy-
sis is that an LC column may be used as the source
for the proteins entering the ESI mass spectrometer,
which facilitates automation. A novel linear ion trap
(LIT) mass spectrometer with MALDI and ESI ion-
ization sources has been built in the MALDI-LIT-ESI
configuration. The design features two independent
ion source/ion optical channels connected to opposite
ends of a single mass analyzer (16 ).
Matrix-assisted laser desorption/ionization
Ionization by MALDI involves a protein suspended
or dissolved in a crystalline structure (the matrix)
of small, organic, and UV-absorbing molecules. The
crystal absorbs energy at the same wavelength of the
laser that is used to ionize the protein. The laser en-
ergy strikes the matrix to cause rapid excitation of
the matrix, and then the matrix and analyte ions are
subsequently passed into gaseous phase. The prin-
cipal ion detected using threshold laser intensity for
MALDI is (M+H+), although signals for multiply
charged ions and oligomeric forms of the analyte may
be seen, especially for large proteins. The ionized pro-
tein is accelerated by an electrostatic field and ex-
pelled into a flight tube. As it exits the flight tube,
the mass analyzer is encountered. The analyzer is of-
ten a time-of-flight (TOF) analyzer. This is based
on the principle that when accelerated by applica-
tion of a constant voltage, the velocity with which
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an ion reaches the detector is determined by its mass.
MALDI is able to analyze proteins down to femtomole
quantities. It can tolerate small amounts of contami-
nants. The information obtained from MALDI anal-
ysis can be automatically submitted to a database
search for further examination (17 ). Currently, there
is a development of direct analysis and MALDI imag-
ing of formalin-fixed, paraffin-embedded (FFPE) tis-
sue sections using the strategy based on in situ en-
zymatic digestion of the tissue section after paraffin
removal. The investigators therefore pinpointed the
exact locations of proteins in an FFPE sample and an-
ticipated that adding protein profiles to histological
data would help physicians with difficult diagnoses
(18 ).
Surface-enhanced laser desorption/ionization
SELDI is designed to perform mass spectrometric
analysis of protein mixtures retained on chromato-
graphic chip surfaces. Differentially expressed pro-
teins may be determined from these protein profiles
by comparing peak intensity. It can be used for pro-
tein purification, expression profiling, or protein in-
teraction profiling. With only one microliter of sam-
ple, a high resolution mass spectrum following a com-
plete chromatographic separation can be performed.
There are many types of substances bound to the pro-
tein arrays, including antibodies, receptors, ligands,
nucleic acids, carbohydrates, or chromatographic sur-
faces (that is, cationic, anionic, hydrophobic, or hy-
drophilic). Some surfaces have broad specificity that
bind the whole classes of proteins, while others are
highly specific that only a few proteins from a com-
plex sample are bound. After the capture step, the
array is washed to reduce nonspecific binding. When
subjected to short bursts of laser light, the retained
proteins are uncoupled from the array surface and
are analyzed by laser desorption/ionization TOF MS.
Some protein arrays contain antibodies covalently im-
mobilized onto the array surface that capture corre-
sponding antigens from a complex mixture. Many
analyses can be followed, for example, analysis of pro-
teolytic digests of the proteins bound to the array can
disclose the antigenic determinant, other proteins of
interest can be immobilized on the array, bound re-
ceptors can reveal ligands, and binding domains for
protein-protein interactions can be detected. The
power of the technology is the integration of on-chip
selective capture, relative or absolute quantitation,
and partial characterization of proteins and peptides
from small samples, which allows rapid protein discov-
ery and differential expression analysis. However, a
difficulty of SELDI is that proteins must often remain
folded in the correct conformation during the prepara-
tion and incubation with the array for protein-protein
interactions to occur (19 ).
Linear ion trap quadrupole-Orbitrap mass
spectrometry
Linear ion trap quadrupole (LTQ)-Orbitrap MS cou-
ples an LIT mass spectrometer to an Orbitrap
mass analyzer via a radio frequency-only trapping
quadrupole with a curved axis. The latter injects
pulsed ion beams into a rapidly changing electric field
in the Orbitrap wherein they are trapped at high ki-
netic energies around an inner electrode. Image cur-
rent detection is subsequently performed after a sta-
ble electrostatic field is achieved. Fourier transforma-
tion of the acquired transient allows wide mass range
detection with high resolving power, mass accuracy,
and dynamic range. The entire instrument operates
in LC/MS mode (1 spectrum/s) with nominal mass
resolving power of 60,000 and uses automatic gain
control to provide high accuracy mass measurements,
within 2 ppm using internal standards and within 5
ppm with external calibration. The maximum resolv-
ing power exceeds 100,000 full width at half maxi-
mum. Rapid, automated data-dependent capabilities
enable real-time acquisition of up to 3 high mass accu-
racy MS/MS spectra per second (20 ). LTQ-Orbitrap
MS is often used as a powerful tool in top-down pro-
teomics with its high performance for mass spectro-
metric protein characterization (21 , 22 ).
Protein identiﬁcation
MS can also be used to identify proteins. Proteolytic
digestion of gel-separated proteins into peptides and
mass analysis of the peptides provide a peptide mass
fingerprint, which can be searched against theoreti-
cal fingerprints of sequences in the databases. Alter-
natively, the peptides can be sprayed into a tandem
mass spectrometer that has the ability to resolve pep-
tides, isolate one peptide, and dissociate it into amino
or carboxy terminal containing fragments. Although
it is more complex than the peptide mass approach,
the sequence information is more specific for the iden-
tification of a protein than a list of peptide masses.
The data can be used to search protein sequence
and nucleotide databases. Protein identification us-
ing ESI-MS/MS can be fully automated. This in-
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volves using three quadrupole mass analyzers in se-
ries. Peptides resulting from chemical or enzymatic
cleavage are separated by high performance LC and
sent to the first analyzer. One peptide is chosen by
the first quadrupole, passed to the second quadrupole
where it is fragmented, and the fragmented ions are
analyzed by the third quadrupole. The difference be-
tween neighboring ions in the product ion spectrum
represents the amino acid at that position of the se-
quence and its mass can be determined by subtrac-
tion. The data may also be analyzed by application of
algorithms and comparison with theoretical product-
ion spectra of proteins in the databases (23 ). On the
other hand, the shotgun proteomics strategy, based on
digesting proteins into peptides and sequencing them
using tandem MS, has become widely adopted (24 ).
There is also a new fast method for identification and
characterization of proteolytic digests of proteins by
monolithic LC coupled with MS. The advantages of
the monolithic columns are a high-pressure stability
and low back pressure, resulting in higher flow rates
for capillary or nanosize columns simplifying the sys-
tem handling. It is successfully applied for the detec-
tion of PTMs and the analysis of membrane proteins
(25 ).
Post-translational modification
Proteomics has the significant advantage of being
able to discern not only changes in expression lev-
els but also in PTMs. Proteomics-based profiling
uniquely allows delineation of global changes in ex-
pression patterns resulting from transcriptional and
post-transcriptional control, PTMs, and shifts in pro-
teins between cellular compartments (26 ). Analysis
of a protein for PTM such as phosphorylation or gly-
cosylation is very important for understanding issues
such as activity, stability, and turnover. Peptides that
do not have the expected molecular mass are fur-
ther analyzed. Post-translational regulation of pro-
teins via protein phosphorylation is one of the ma-
jor means of protein regulation. Phosphorylation is
a very rapid and reversible method of changing the
function of proteins (27 ). Reversible protein phospho-
rylation is crucially involved in all aspects of cell phys-
iology. The highly challenging task of revealing and
characterizing the dynamic protein phosphorylation
networks has only recently begun to become feasible.
MS is especially useful for the analysis of expressed
proteins with PTM, such as alkylation, glycosylation,
and phosphorlylation, which may be the most impor-
tant regulatory proteins in a biological cell. To iden-
tify the specific sites of modification in the analysis
of enzymatically digested protein, tandem MS with
collision-induced dissociation of peptides inside MS
can be used (28 ). Immobilized metal affinity chro-
matography is most useful for phosphopeptide enrich-
ment after methylation of the peptides in the com-
plex protein digests. The subsequent tandem MS of
the isolated phosphopeptides results in both the iden-
tification of phosphorylated proteins and the mapping
of the in vivo phosphorylation sites (29 ). Phospho-
proteins can be revealed by comparing the map of
a sample digested with a proteolytic enzyme to the
same sample digested with the proteolytic enzyme and
a phosphatase. Similarly, n-linked sugars can be de-
tected by use of glycosylases. Antibodies recognizing
phosphotyrosines or phosphoserines confirm the pres-
ence of phosphate groups. These phosphoantibodies
can be employed to precipitate phosphorylated pro-
teins before MS. In addition to MS, stains are also
used to detect phosphoproteins in polyacrylamide gels
(30 ). Proteomics approaches have been used for a
number of PTM studies. For example, Odhiambo et
al have used MALDI-TOF MS and LC-MS/MS to
identify oxidative PTMs of serum albumin in patients
with idiopathic pulmonary arterial hypertension and
pulmonary hypertension of sickle cell anemia (31 ).
Phage display
Another technique making an important contribution
to proteomics is phage display. It involves the cre-
ation of peptide or protein libraries on viral surfaces
that are screened for activity as a group. The pep-
tides or proteins remain associated with their corre-
sponding genes allowing identification. An alterna-
tive to phage display is cloning of ligand targets. It
uses ligands, which are small peptide sequences that
bind to larger domain units within proteins, to dis-
cover new domains and subsequently new proteins
(32 ). Phage display has been used extensively in
vitro and in animal models to generate ligands and to
identify disease-relevant targets. A series of patients
have been reported to receive phage library for serial
panning of disease targeting ligands (33 ). For exam-
ple, Geuijen et al have obtained a panel of myeloid
cell binding single chain variable fragments by apply-
ing phage display selection on myeloid cell lines, fol-
lowed by the identification of several antibody target
molecules on malignant cells (34 ).
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Bioinformatics
Bioinformatics is an integration of mathematical, sta-
tistical, and computational methods to analyze bio-
logical, biochemical, and biophysical data. Sophis-
ticated bioinformatics tools are being developed to
handle the vast quantity of data resulting from ge-
nomics and proteomics studies. Collections of pro-
teomics databases for organisms contain biological
information on proteins that assists with annotat-
ing and interpreting experimental results from pro-
teomics studies. Databases of computationally de-
rived protein structures are available to aid in the
design of molecules capable of interacting with a pro-
tein of interest (35 ). A wide range of research areas
in bioinformatics, molecular biology, and medicinal
chemistry require precise chemical structure informa-
tion about molecules and reactions, such as drug de-
sign, ligand docking, metabolic network reconstruc-
tion, and systems biology. A database of metabolites
called BioMeta that augments the existing pathway
databases by explicitly assessing the validity, correct-
ness, and completeness of chemical structure and re-
action information has been recently presented (36 ).
Bioinformatics tools are essential for converting raw
proteomics data into knowledge and subsequently into
useful applications. A good example would be the
development of methodology for predicting protein-
protein interactions by Shen et al based on sequence
information (37 ).
Challenges and Perspectives
Challenges
There are several difficulties in the study of proteins
that are not inherent in the study of nucleic acids.
Proteins are more difficult to work with than DNA
and RNA. They have secondary and tertiary structure
that must often be maintained during their analysis.
Proteins can be denatured by the action of enzymes,
heat, light, or by aggressive mixing as in beating egg
whites. Some proteins are difficult to analyze due to
their poor solubility.
On the other hand, proteins cannot be amplified
like DNA, therefore less abundant species are more
difficult to detect. Approximately half of the to-
tal protein content in plasma comes from albumin
(∼55 mg/mL), and together with another 10 pro-
teins, they make up 90% of the total content. Low
abundant proteins such as cytokines are normally
present at 1–5 pg/mL. Each proteomics technology
can only analyze proteins within 3–4 orders of magni-
tude, and mostly at the higher concentration end of
the spectrum. The removal of high abundant pro-
teins from plasma or serum is thus a prerequisite
for conducting more detailed proteomics studies on
low abundant proteins. However, many potentially
important biomarkers may be lost in this process
due to non-specific binding or the co-removal of pro-
teins/peptides intrinsically bound to the high abun-
dant carrier proteins. In particular albumin, removal
has been shown to result in significant loss of cy-
tokines (38 ). Thulasiraman et al developed the new
deep proteome approach via ligand library beads. The
use of equalizer beads coupled with a combinatorial
library of ligands has been shown to allow access of
many low abundant proteins or polypeptides unde-
tectable by classical analytical methods. The popula-
tion of beads has such diversity that a binding part-
ner should exist for most proteins in a sample. Each
bead has an equivalent binding capacity. High abun-
dant proteins saturate their binding partners and the
excess proteins are washed away, whereas trace pro-
teins are concentrated on their specific affinity lig-
ands. This panoply of methods could offer a strong
step forward in “mining below the tip of the iceberg”
for detecting the “unseen proteome” (39 ).
To tackle with the sensitivity issue, Nettikadan
et al constructed the ultramicroarrays, combining
the advantages of microarray including multiplex-
ing capabilities, higher throughput, and cost savings
with the ability to screen very small sample volumes.
These ultramicroarrays were found to have a high
specificity and sensitivity with detection levels using
purified proteins in the attomole range. This strat-
egy enables the proteomics analysis of materials that
are available in very limited quantities, such as those
collected by laser capture microdissection, neonatal
biopsy microspecimens, and forensic samples (40 ).
Apparently, a number of technical obstacles re-
main before routine proteomics analysis can be
achieved in the clinic. However, the standardiza-
tion of methodologies and dissemination of proteomics
data into publicly available databases is starting to
overcome these hurdles. The cost is also a precluding
factor for the widespread use of proteomics in clinical
laboratory. Most proteomics technologies use com-
plex instrumentation, critical computing power, and
expensive consumables. Another major challenge will
be the integration of proteomics with genomics and
metabolomics data, as well as their functional inter-
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pretation in conjunction with clinical results and epi-
demiology (41 ).
Perspectives
With the availability of DNA microarray analysis per-
mitting the expression of thousands of genes to be
monitored simultaneously, it may be asked why pro-
teomics is so important. The importance of the pro-
teome cannot be overstated as it is the proteins within
the cell that provide structure, produce energy, as
well as allow communication, movement, and repro-
duction. Basically, proteins provide structural and
functional framework for cellular life. Genetic infor-
mation is static while the protein complement of a cell
is dynamic.
Differential proteomics is a scientific discipline
that detects the proteins associated with a disease by
means of their altered levels of expression between
the control and disease states. It enables correlations
to be drawn between the range of proteins produced
by a cell or tissue and the initiation or progression
of a disease state. Proteomics research permits the
discovery of new protein markers for diagnostic pur-
poses and the study of novel molecular targets for
drug discovery. The protein markers identified have
a broad range of potential applications. They may
be used for clinical diagnostic or prognostic purposes.
Biomarkers may also be used to help devising an op-
timal therapeutic treatment plan for different patient
subsets and to monitor the effect of treatment. In
this way, protein markers may be used to accelerate
the speed and efficacy of clinical trials. If further bio-
chemical research reveals that proteins have a causal
role in disease pathology, they may have the utility as
molecular targets for therapeutic intervention in the
disease.
Proteomics has much promise in novel drug dis-
covery via the analysis of clinically relevant molecular
events. New types of proteomics technologies com-
bined with advanced bioinformatics are currently be-
ing used to identify molecular signatures of diseases
based on protein pathways and signaling cascades.
Applying their findings will improve our understand-
ing of the roles of individual proteins or the entire
cellular pathways in the initiation and development
of disease. It is envisaged that analyzing the cellular
circuitry of ongoing molecular networks will become
a powerful clinical tool in individualized patient man-
agement (42 ).
The abundance of information provided by pro-
teomics research is entirely complementary with the
genetic information being generated by genomics re-
search. Proteomics makes a key contribution to the
development of functional genomics. The combina-
tion of genomics and proteomics will play a major
role in biomedical research, and it will have a sig-
nificant impact on the development of diagnostic and
therapeutic products in the future.
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